Melatonin Dose-effect Relation in Childhood Autism (MELADOSE)
Sponsor: Centre Hospitalier Guillaume Régnier, RENNES
Listed as NCT01780883, this PHASE2 trial focuses on Childhood Autism and remains completed. Sponsored by Centre Hospitalier Guillaume Régnier, RENNES, it has been updated 7 times since 2013, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Guillaume Régnier, RENNES
- Rennes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .